RSRobbert R. Struyven

Robbert R. Struyven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robbert R. Struyven has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Reticular Pseudodrusen Burden and Dark Adaptation in Nonadvanced Age-Related Macular Degeneration

    by Ariel Yuhan Ong, Robbert R. Struvyen, David A. Merle, Kevin Mendez, Helia Ashourizadeh, Souvick Mukherjee, Afonso Lima-Cabrita, Jooyoung Chang, Dylan Wu, Shrinivas Pundlik, et al.

  • Open Access

    Epidemiology, Clinical Features, and Visual Outcomes After Intraocular Foreign Body Removal

    by Ariel Yuhan Ong, Eric A. Goldberg, William C. Kearney, Connor Ross, Caroline Awh, David A. Merle, Siegfried K. Wagner, Robbert R. Struyven, Pearse A. Keane, Tobias Elze, et al.


  • Longitudinal Evaluation of Microvascular Changes and Imaging Biomarkers Associated with Visual Prognosis in Retinal Artery Occlusion

    by Chong Chen, Kayla N. Nodecker, Rajiv M. Sastry, Leiyu Wang, Xinyi Ding, Ying Zhu, Francesco Romano, Filippos Vingopoulos, Robbert R. Struyven, Ioanna Ploumi, et al.


  • Open Access

    Dynamics of retinal changes in early-stage Parkinson’s disease

    by Ane Murueta-Goyena, Sara Teijeira-Portas, Elisa Blanco Martín, Raquel Vázquez-Picón, Blanca Ruiz Bajo, Jone Bocos, Jorge Sánchez-Molina, Patricia Alves Dias, Ioana Croitoru, Iñaki Rodríguez Agirretxe, et al.

    Parkinson’s disease (PD) is a neurodegenerative disorder primarily characterized by motor symptoms, with emerging evidence suggesting retinal pathology, particularly in the ganglion cell-inner plexiform layer (GCIPL), detectable via optical coherence tomography (OCT). This study aimed to characterize early retinal dynamics in PD using OCT. We conducted a prospective one-year longitudinal multicenter study involving 53 early-stage PD patients with a disease duration of 5 years or less and 52 controls. The participants underwent retinal spectral-domain OCT, primary visual function and cognitive examinations. We examined baseline retinal measures and short-term longitudinal differences between groups via linear mixed effects models. In PD patients, the baseline GCIPL thickness in central regions was increased by up to 4 μm, and the rate of thinning in the parafoveal GCIPL was − 0.61 [0.29] µm/year faster over a one-year follow-up period than in controls in the 2- to 3-mm ring (p = 0.039). In PD patients, greater central GCIPL thickness was associated with poorer contrast sensitivity and reduced performance on the Farnsworth D15 color vision test. It also predicted subsequent thinning in both the GCIPL (2- to 3-mm ring) and the inner nuclear layer (2- to 5-mm rings). However, this increased thickness was not linked to prevalent or progressive motor or cognitive manifestations. In conclusion, this study provides the first detailed topographical description of early retinal dynamics in PD patients, revealing increased central GCIPL thickness and accelerated parafoveal GCIPL thinning in PD. However, the macular region shows complex and variable dynamics among PD patients, but these changes precede detectable progression in clinical scales.


  • Open Access

    Artificial intelligence to facilitate clinical trial recruitment in age-related macular degeneration

    by Dominic J. Williamson, Robbert R. Struyven, Fares Antaki, Mark A. Chia, Siegfried K. Wagner, Mahima Jhingan, Zhichao Wu, Robyn Guymer, Simon S. Skene, Naaman Tammuz, et al.

    Background Recent developments in artificial intelligence (AI) have positioned it to transform several stages of the clinical trial process. In this study, we explore the role of AI in clinical trial recruitment of individuals with geographic atrophy (GA), an advanced stage of age-related macular degeneration, amidst numerous ongoing clinical trials for this condition. Methods Using a diverse retrospective dataset from Moorfields Eye Hospital (London, United Kingdom) between 2008 and 2023 (602,826 eyes from 306,651 patients), we deployed a deep learning system trained on optical coherence tomography (OCT) scans to generate segmentations of the retinal tissue. AI outputs were used to identify a shortlist of patients with the highest likelihood of being eligible for GA clinical trials, and were compared to patients identified using a keyword-based electronic health record (EHR) search. A clinical validation with fundus autofluorescence (FAF) images was performed to calculate the positive predictive value (PPV) of this approach, by comparing AI predictions to expert assessments. Results The AI system shortlisted a larger number of eligible patients with greater precision (1,139, PPV: 63%; 95% CI: 54–71%) compared to the EHR search (693, PPV: 40%; 95% CI: 39– 42%). A combined AI-EHR approach identified 604 eligible patients with a PPV of 86% (95% CI: 79–92%). Intraclass correlation of GA area segmented on FAF versus AI-segmented area on OCT was 0.77 (95% CI: 0.68–0.84) for cases meeting trial criteria. The AI also adjusts to the distinct imaging criteria from several clinical trials, generating tailored shortlists ranging from 438 to 1,817 patients. Conclusions We demonstrate the potential for AI in facilitating automated pre-screening for clinical trials in GA, enabling site feasibility assessments, data-driven protocol design, and cost reduction. Once treatments are available, similar AI systems could also be used to identify individuals who may benefit from treatment.


  • Open Access

    Periodontitis and Outer Retinal Thickness: a Cross-Sectional Analysis of the United Kingdom Biobank Cohort

    by Siegfried K. Wagner, Praveen J. Patel, Josef Huemer, Hagar Khalid, Kelsey V. Stuart, Colin J. Chu, Dominic J. Williamson, Robbert R. Struyven, David Romero-Bascones, Paul J. Foster, et al.


  • Top Cited Papers
    Open Access

    A foundation model for generalizable disease detection from retinal images

    by Yukun Zhou, Mark A. Chia, Siegfried K. Wagner, Murat S. Ayhan, Dominic J. Williamson, Robbert R. Struyven, Timing Liu, Moucheng Xu, Mateo G. Lozano, Peter Woodward-Court, et al.

    Medical artificial intelligence (AI) offers great potential for recognizing signs of health conditions in retinal images and expediting the diagnosis of eye diseases and systemic disorders1. However, the development of AI models requires substantial annotation and models are usually task-specific with limited generalizability to different clinical applications2. Here, we present RETFound, a foundation model for retinal images that learns generalizable representations from unlabelled retinal images and provides a basis for label-efficient model adaptation in several applications. Specifically, RETFound is trained on 1.6 million unlabelled retinal images by means of self-supervised learning and then adapted to disease detection tasks with explicit labels. We show that adapted RETFound consistently outperforms several comparison models in the diagnosis and prognosis of sight-threatening eye diseases, as well as incident prediction of complex systemic disorders such as heart failure and myocardial infarction with fewer labelled data. RETFound provides a generalizable solution to improve model performance and alleviate the annotation workload of experts to enable broad clinical AI applications from retinal imaging.